IRWD
Ironwood Pharmaceuticals, Inc. Class A · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website ironwoodpharma.com
- Employees(FY) 219
- ISIN US46333X1081
Performance
+5.68%
1W
-25.0%
1M
-17.52%
3M
-41.42%
6M
-67.48%
YTD
-63.57%
1Y
Profile
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Technical Analysis of IRWD 2024-12-09
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2024-12-03 19:00
IRWD: What does Argus have to say about IRWD?(Argus Research)
- 2024-11-26 19:00
IRWD: What does Argus have to say about IRWD?(Argus Research)
- 2024-11-26 16:01
- 2024-11-26 03:01
- 2024-11-13 16:01
- 2024-11-13 03:01
- 2024-11-12 19:00
IRWD: What does Argus have to say about IRWD?(Argus Research)
- 2024-11-08 11:03
- 2024-11-08 04:01
- 2024-11-07 08:15
- 2024-11-07 07:20
Ironwood: Q3 Earnings Snapshot(Associated Press Finance)
- 2024-11-07 07:00
Ironwood Pharmaceuticals Reports Third Quarter 2024 Results(Business Wire)
- 2024-11-06 18:00
- 2024-11-06 07:29
- 2024-11-05 19:00
IRWD: Raising target price to $4.00(Argus Research)
- 2024-10-28 09:42
- 2024-10-28 07:00
- 2024-10-27 19:00
- 2024-10-24 16:00
- 2024-10-24 04:00
- 2024-10-16 13:06
- 2024-10-16 08:58
- 2024-10-09 17:36
- 2024-10-08 20:00
IRWD: What does Argus have to say about IRWD?(Argus Research)
- 2024-09-17 08:40
- 2024-09-09 07:53
- 2024-09-01 22:26
- 2024-09-01 10:26
- 2024-08-29 16:01
- 2024-08-29 08:41
10 Best Multibagger Penny Stocks of 2025(Insidermonkey)
Page 1 of 8
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.